Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

291
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
291
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

260
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
260
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

226
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
226
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

254
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
254
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

2.6K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.6K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

85
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
85

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From human hand joints to continuum robot: how articular surface morphology shapes flexibility and stability in template-based designs.

Bioinspiration & biomimetics·2025
Same author

Automatic pelvic fracture segmentation: a deep learning approach and benchmark dataset.

Frontiers in medicine·2025
Same author

FracFormer: Fracture Reduction Planning With Transformer-Based Shape Restoration and Fracture Data Simulation.

IEEE transactions on medical imaging·2025
Same author

Preoperative fracture reduction planning for image-guided pelvic trauma surgery: A comprehensive pipeline with learning.

Medical image analysis·2025
Same author

Automatic path planning for pelvic fracture reduction with multi-degree-of-freedom.

Computer methods and programs in biomedicine·2025
Same author

Time course of cardiac rupture after acute myocardial infarction and comparison of clinical features of different rupture types.

Frontiers in cardiovascular medicine·2024

Related Experiment Video

Updated: Sep 14, 2025

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.9K

Thyroid dysfunction and pulmonary arterial hypertension: A bidirectional mendelian randomization study.

Gongli Pang1, Xiaoxia Wang2, Ru Zhao1

  • 1Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China.

International Journal of Cardiology. Heart & Vasculature
|July 21, 2025
PubMed
Summary

Hypothyroidism is causally linked to an increased risk of Pulmonary Arterial Hypertension (PAH). This study used Mendelian Randomization to investigate the association between thyroid dysfunction and PAH, finding no reverse causation.

Keywords:
Mendelian randomizationPulmonary arterial hypertensionThyroid dysfunction

More Related Videos

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.4K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

377

Related Experiment Videos

Last Updated: Sep 14, 2025

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.9K
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.4K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

377

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Genetic Epidemiology

Background:

  • Thyroid dysfunction is implicated in cardiovascular diseases.
  • A potential link exists between thyroid dysfunction and increased Pulmonary Arterial Hypertension (PAH) risk.
  • The causal nature of this association requires investigation.

Purpose of the Study:

  • To investigate the causal association between thyroid dysfunction and PAH.
  • Utilized bidirectional two-sample Mendelian Randomization (MR) analysis.

Main Methods:

  • Exposure factors included thyroid dysfunction markers (FT3, FT4, TSH, hyperthyroidism, hypothyroidism).
  • Pulmonary Arterial Hypertension (PAH) served as the outcome factor.
  • Analyzed bidirectional causality using Inverse Variance Weighting (IVW), MR-Egger, and Weighted Median methods, assessing heterogeneity and pleiotropy.

Main Results:

  • Hypothyroidism significantly increased PAH risk (OR = 1.485, P = 0.025).
  • Free triiodothyronine (FT3), free thyroxine (FT4), thyrotropin (TSH), and hyperthyroidism showed no association with PAH risk.
  • No evidence of a reverse causal association from PAH to thyroid dysfunction was found.

Conclusions:

  • Hypothyroidism is causally associated with an elevated risk of Pulmonary Arterial Hypertension (PAH).
  • Further research is warranted to elucidate the complex relationship between thyroid dysfunction and PAH.